Ignacio Asial

Founder and CEO
DotBio Pte. Ltd

​
​Dr. Ignacio Asial is the Chief Executive Officer and Founder of DotBio, a Singapore-born biopharma company specialized in next-generation antibody therapies, with a particular focus on multi-specific antibodies for immuno-oncology.  He is also an Adjunct Assistant Professor at Nanyang Technological University.
Prior to launching DotBio, Dr. Asial held diverse scientific positions. He worked in academia in institutions such as Nanyang Technological University (Singapore), University of California San Francisco (USA), and Centre National de la Recherche Scientifique (France), as well as in the private sector at Ambrilia Biopharma (France) and Genentech (USA).
Dr. Asial obtained a M. Eng. in Biotechnology from Ecole Supérieure d’Ingénieurs de Luminy / Polytech Marseille (France), a M.Sc. in Biochemistry, Structural Biology, Bioinformatics and Genomics from Aix-Marseille University (France), and a Ph.D. in Biological Sciences from Nanyang Technological University (Singapore). He specializes in technology development, in particular in the fields of antibody engineering and directed evolution.